Back to search

Netherlands· NL-285a07cbcc9f

Lynkuet 60 mg zachte capsules

A elinzanetant product containing elinzanetant, registered in Netherlands by Bayer AG. The same ATC class is registered in 10 of our 19 countries.

ATC G02CX07

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLynkuet 60 mg zachte capsulesATCG02CX07REGISTER NO.NL-285a07cbcc9fPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Elinzanetant is registered in 10 of 19 countries.

Countries holding a registration under ATC G02CX07 (elinzanetant), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Elinzanetant · ATC G02CX07

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ELINZANETANT
Manufacturer
Bayer AG
Country
Netherlands (NL)
ATC code
G02CX07
ATC class
Elinzanetant
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1991

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Elinzanetant in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All elinzanetant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lynkuet
  • Liechtenstein · Lynkuet
  • Norway · Lynkuet

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/44110045-fcad-401c-9225-229247168e80
GET /v1/drugs/44110045-fcad-401c-9225-229247168e80?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, zacht",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/lynkuet-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Elinzanetant",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134252",
  "excipients": [
    "AMMONIA (E 527)",
    "CAPRYLOCAPROYLMACROGOLGLYCERIDEN",
    "FOSFATIDYLCHOLINE, SOYA",
    "GELATINE (E 441)",
    "GLYCEROL (E 422)",
    "GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
    "GLYCERYLMONO-OLEAAT",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "MACROGOL 400",
    "POLYSORBAAT 80 (E 433)",
    "POLYVINYLACETAAFTALAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SORBITOL VLOEIBAAR, GEDEELTELIJK GEDEHYDRATEERD",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)",
    "TOCOFEROL, DL-ALFA (E 307)",
    "TRIGLYCERIDEN MIDDELLANGE KETEN",
    "WITTE INKT"
  ],
  "substances": [
    "ELINZANETANT"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/11/17",
  "procedure_number": "EMEA/H/C/006298",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1991",
  "additional_monitoring": "Y"
}

See everything about elinzanetant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.